The Food & Drug Administration (“FDA” or the “Agency”) has pushed forward its latest actions in the ongoing LDT (Laboratory Developed Tests) scenario by publishing its much-anticipated proposed rule on LDTs, according to King & Spalding.
The proposed rule, which opened up to public comment till December 2, 2023, marks a significant step by the FDA in its ongoing activities surrounding LDTs, providing a profound impact on corporations and law firms dealing with related matters.
Previous FDA interventions regarding LDTs have generated considerable debate, intertwining stringent regulatory adjustments with scientific advancements. The publication of this set of proposed rules will offer an invaluable perception into the FDA’s existing regulatory approach towards LDTs.
LDTs are custom, often one-of-a-kind tests developed and utilized within a single laboratory. They’ve held a unique position within regulatory landscapes due to their scientific complexity, importance in patient care and because they are not manufactured or sold in a traditional sense, which poses specific challenges to their regulation and oversight.
Needless to say, stakeholders (ranging from hospital and pharmaceutical corporations to independent diagnostic labs and public health institutions) should stay engaged in this continuing discourse to keep aligned with any varying regulatory expectations and to contribute their perspectives to the ongoing dialogue.
Though the full text of the proposed rule is not available to the wider public at the moment, corporations and law firms with a keen interest in the subject matter are recommended to follow the updates closely, and contribute to the public commentary if able prior to the December 2 deadline.
This ongoing conversation about LDTs regulation is of utmost importance for the legal and corporate world. It is essential for these entities to stay updated, adaptive and proactive regarding LDTs in order to navigate the stormy seas of FDA regulation effectively.